SCHMC

Clinical usefulness of two-phase 18F-sodium-fluoride (18F-NaF) bone PET/CT for evaluating treatment response of bone metastases from breast cancer: Case report

Metadata Downloads
Abstract
We report the case of a breast cancer patient in whom a two-phase 18F-sodium-fluoride (18F-NaF) bone PET/CT was useful for detecting hidden bone metastases and assessing treatment response. The patient underwent a two-phase bone PET/CT to evaluate a newly developed lesion found on bone scintigraphy following surgery. In the perfusion and bone phase PET/CT images, focally increased perfusion and bony uptake were found in the sacrum and L5 vertebra, suggesting bone metastases of breast cancer. Therefore, the patient subsequently underwent palliative treatment. In another two PET/CT studies (each including two-phase bone images) performed after three and six months of follow-up, the perfusion phase images showed an improvement of the lesion uptake more clearly than in the bone phase images in the visual and semi-quantitative analyses, and thus the perfusion phase images were more useful for clarifying the treatment response earlier than the bone phase images. This is the first case showing the clinical usefulness of 18F-NaF bone PET/CT with the perfusion imaging technique for evaluating bone metastases and the therapeutic response of metastatic bone lesions.
All Author(s)
J. H. Seo ; S. M. Lee ; S. N. Yu ; J. W. Lee ; J. E. Lee
Issued Date
2019
Type
Article
Keyword
(18)F-fluoruro de sodio(18)F-sodium fluorideBreast cancerCáncer de mamaPositron emission tomographyTomografía por emisión de positrones
Publisher
Sociedad Española de Medicina Nuclear e Imagen Molecular
ISSN
2253-8089
Citation Title
Revista española de medicina nuclear e imagen molecular
Citation Volume
38
Citation Number
4
Citation Start Page
238
Citation End Page
242
Language(ISO)
eng
DOI
10.1016/j.remn.2018.09.009
URI
http://schca-ir.schmc.ac.kr/handle/2022.oak/1952
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.